Navigation Links
Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
Date:8/27/2013

e Light Study to cost more than what is projected; the potential for early termination of Orexigen's North American collaboration agreement with Takeda Pharmaceutical Company Limited; the costs and time required to complete additional clinical, non‐clinical or other requirements prior to any resubmission of the Contrave NDA; the therapeutic and commercial value of Contrave; Orexigen's ability to maintain sufficient capital to fund our operations through potential approval of Contrave in 2014; Orexigen's ability to enter into a collaborative partnership for Contrave outside North America on acceptable terms, if at all; and other risks described in Orexigen's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward‐looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in Orexigen's Annual Report on Form 10‐K filed with the Securities and Exchange Commission March 14, 2013 and its other reports, which are available from the SEC's website (www.sec.gov) and on Orexigen's website (www.orexigen.com) under the heading "Investor Relations." All forward‐looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

 Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen Therapeutics to Present at Upcoming Conferences
2. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
3. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
6. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
7. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
8. Nile Therapeutics Reports 2011 Third Quarter Financial Results
9. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
10. Fate Therapeutics Strengthens Its iPSC Platform
11. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... JH Technologies announces the ... Irvine. JH Technologies, a leader in sales and ... an expanded partnership with Leica Microsystems into the Southern ... analysis solutions will be featured at the grand opening ... showroom facility is located within the JH Technologies office’s ...
(Date:9/17/2014)... 17, 2014 Terracon Corporation has announced ... TerraPure tank . This addition to the company’s ... FDA-compliant linear polyethylene and available in 125 or 250 ... ships in two weeks or less. , The new ... found in Terracon’s existing TerraPure tank line – plus ...
(Date:9/17/2014)... 17, 2014 Alternative Fuels Americas, Inc. (AFAI) announced ... Special Purpose Vehicle in partnership with Jatro Greentech, Inc., a ... company. The SPV shall be called AFAI Jatro Green Ethiopia ... majority shareholder. The SPV shall pursue Jatropha planting and biofuels ... Ethiopia . "Although we have ...
(Date:9/17/2014)... RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... has been granted a patent by the United ... delivery system for delivering its "original" RNAi compounds ... treatment of diseases with an inflammatory component. Potential ...
Breaking Biology Technology:JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 2JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 3Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4
... The world,s smallest chess board about the diameter ... were winners in this year,s design contest for, respectively, ... National Laboratories in mid May. The two winning ... facility, one of the most advanced in the world. ...
... Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer ... its AspirinWorks® Test June 17-19 at the Pri-Med New York ... Convention Center in New York, N.Y. , ... Corgenix representatives will be on-hand during the conference ...
... New data from a retrospective cohort study showed that up ... (GID) that can have a substantial adverse effect on major PD-related clinical ... Congress of Parkinson,s Disease and Movement Disorders in Buenos Aires, Argentina ... , , ...
Cached Biology Technology:Texas Tech, U of Utah win Sandia microdevice competition 2Texas Tech, U of Utah win Sandia microdevice competition 3Texas Tech, U of Utah win Sandia microdevice competition 4Corgenix to Exhibit AspirinWorks(R) Test at Pri-Med New York 2Corgenix to Exhibit AspirinWorks(R) Test at Pri-Med New York 3New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease 2New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease 3New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease 4
(Date:9/16/2014)... have discovered the "molecular brakes" that time the generation ... mice. These "hair cells" translate sound waves into electrical ... interpreted as sounds. If the arrangement of the cells ... of the research will be published in The ... proteins Hey1 and Hey2 act as brakes to prevent ...
(Date:9/16/2014)... inherit certain traits from our parents that are pre-determined. ... play out by taking certain drugs or better yet, ... team of researchers at the Boston University School of ... research. , Epigenetics regulates gene expression in a ... which prevent permanent mutations or alterations within the gene ...
(Date:9/16/2014)... species has its own bacterial identity. That,s the conclusion ... institutions who studied the genetic fingerprints of bacteria on ... , "This study demonstrates for the first time that ... ecological strategies possess very different microbial communities on their ... postdoctoral researcher in the UO,s Institute of Ecology and ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Microbiome research shows each tree species has a unique bacterial identity 2
... Future of the Nuclear Industry" will be the Plenary Session topic ... taking place June 28-July 1, 2010, at the Salt Palace Convention ... Chair of the Nuclear Regulatory Commission, will be the lead presenter ... Over 250 presentations between June 28 and July 1 will occur ...
... been established for more than 50 years as one ... termed bipolar disorder. However, scientists have never been ... new research from Cardiff University scientists suggests a possible ... better understanding of the illness and potentially more effective ...
... bacteria lead oil companies to change their methods of harvesting ... reducing the carbon dioxide that burning oil and gasoline discharges ... Larter, professor of geoscience and holder of the ... Calgary, was the keynote speaker today for the 2010 Goldschmidt ...
Cached Biology News:55th annual meeting of the Health Physics Society 2
...
...
... The pCITE-2a-c(+) vectors are designed for enhanced translation ... extracts, e.g. rabbit reticulocyte lysate. The maps for ... with the following exceptions: pCITE-2b(+) is a 3793 ... BstX I and Xcm I sites. Subtract 7 ...
...
Biology Products: